Drugs / 2B3-201
2B3-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02048358 | Nov 2013 → Jan 2015 | multiple sclerosis | BBB-Therapeutics B.V. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2B3-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02048358 ↗ |
| Known as | 2B3-201: glutathione PEGylated-liposomal methylprednisolone | “2B3-201: glutathione PEGylated-liposomal methylprednisolone” NCT02048358 ↗ |
| Route | Intravenous | “2B3-201 150mg, once, IV infusion” NCT02048358 ↗ |